Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

Completed · Phase 4

Conditions studied: HIV Infection

In brief

This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate the pharmacokinetics of VIRACEPT

Key facts

Study ID

NCT00246610

Run by

Pfizer

People needed

16

Starts

2006-03-01

Expected to finish

2007-11-01

Last updated by the study team

2011-04-28

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• HIV infection
• Second trimester of pregnancy

You may not qualify if…

• Major current or prior history of obstetrical complications
• Serious current medical diseases
• Evidence of HIV virus resistance to antiretroviral agents

Where it is running

• Pfizer Investigational Site — Jacksonville, Florida, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Metairie, Louisiana, United States
• Pfizer Investigational Site — Detroit, Michigan, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.